Health and Healthcare

Analyst Projecting 50% Upside in Dendreon (DNDN)

Money Stack ImageDendreon Corporation (NASDAQ: DNDN) was started with a Buy rating and a $36.00 target at Deutsche Bank.  The call’s positive expectations are mixed near-term, but the assumption is that Provenge will become a blockbuster product in the fight against metastatic Prostate cancer. After looking through all the notes, it appears that this may be the second highest price target from all of the analysts out there.

Deutsche Bank believes that Dendreon will receive approval in early 2010. The firm does note that near term stock trading may remain range-bound into an the FDA Approval process.  There is a summer analyst meeting where the firm expects Dendreon to provide details on manufacturing and on the company’s marketing strategy.

The expectation is that the approval process will be filed in late 2009 with a subsequent approval in early 2010.  Interestingly enough, Deutsche Bank notes that investors are likely placing too little value on the FDA approval chances.  It also noted that an additional approval in the European Union is not reflected in the shares.

Dendreon is already indicated higher with more than two hours to go before the opening bell.  After a $25.46 close on Thursday, shares are looking up around the $26.75 level.  The 52-week range is $2.55 to $27.40.

Jon C. Ogg
June 5, 2009

Cash Back Credit Cards Have Never Been This Good

Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.

 

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.